Amgen Report Results of Sotorasib in P-II CodeBreaK 100 Study for Advanced Non-Small Cell Lung Cancer

 Amgen Report Results of Sotorasib in P-II CodeBreaK 100 Study for Advanced Non-Small Cell Lung Cancer

Amgen Report Results of Sotorasib in P-II CodeBreaK 100 Study for Advanced Non-Small Cell Lung Cancer

Shots:

  • The P-ll CodeBreaK 100 study involves assessing of Sotorasib (proposed INN for AMG 510, 960mg) in 126 patients with KRAS G12C-mutant advanced NSCLC, whose cancer had progressed despite prior treatment with CT and/or immunotherapy
  • Result: ORR is consistent with previously reported P-I study while other measures of efficacy including DoR are promising and 50%+ of the responders were still on treatment and continuing to respond as of the data cutoff date whereas safety & tolerability is similar to previous P-I data
  • Detailed results of the P-II study will be submitted to the IASLC 2020 World Congress on Lung Cancer while the company has begun recruiting in P-III CodeBreaK 200 study evaluating Sotorasib vs docetaxel  in KRAS G12C-mutant NSCLC patients

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post